Abstract
Introduction: Preoperative polymicrobial urine cultures are common, but the associated risk of nosocomial infection is currently unknown. We aimed to analyze the risk of postoperative infection in patients with preoperative polymicrobial urine cultures. Methods: This was a prospective cohort study conducted from November 2018 to October 2020. Polymicrobial urine cultures were defined by at least the presence of 3 bacteria without leukocyturia threshold on two consecutive samples in the month preceding the surgical procedure. Data on postoperative infections were collected during hospitalization until day 30. A postoperative infection was defined by the occurrence of clinical signs (fever, chills, and suppurated process on the surgical site) associated with the prescription of an antibiotic therapy. Results: Sixty-eight patients were included, and seven developed a postoperative infection with a microbe identified in blood or urine cultures. There was a significant association between leukocyturia ≥104 (p = 0.02) and the administration of intraoperative antibiotic prophylaxis (p < 0.001). In contrast, there was no significant association between postoperative infections for patients with polymicrobial preoperative urine cultures and having received or not an empirical antibiotic therapy. Conclusion: The rate of postoperative infection in patients with polymicrobial urine culture before urological procedure was 10.2%. Further studies are needed to assess the antibiotic prophylaxis to be used in this situation.
References
1.
Cheadle
WG
. Risk factors for surgical site infection
. Surg Infections
. 2006
;7
(Suppl 1
):S7
–11
. .2.
Bruyère
F
. Expose journee urorisq
. [cited 2013 Apr 6]. Available from: https://www.urofrance.org/fileadmin/medias/accreditation/oa/journee-urorisq/2013-04-06/expose-ecbu-bruyere.pdf.3.
SFAR
. Recommandations formalisées d’experts. Antibioprophylaxie en chirurgie et médecine interventionnelle
. [cited 2018 Jul]. Available from: https://sfar.org/antibioprophylaxie-en-chirurgie-et-medecine-interventionnelle patients-adultes-maj2018/.4.
Bruyère
F
, Sotto
A
, Escaravage
L
, Cariou
G
, Mignard
J-P
, Coloby
P
, Recommendations of the infectious disease committee of the French Association of Urology (AFU): antibiotic prophylaxis for urological procedures
. Prog Urol
. 2010
;20
(2
):101
–8
.5.
SPILF-AFU
. Révision des recommandations de bonne pratique pour la prise en charge et la prévention des Infections Urinaires Associées aux Soins (IUAS) de l’adulte
. [cited 2015 May 4]. Available from: http://www.infectiologie.com/UserFiles/File/medias/Recos/2015-RPC infections_urinaires_associees_aux_soins.pdf.6.
Vallée
M
, Cattoir
V
, Malavaud
S
, Sotto
A
, Cariou
G
, Arnaud
P
, Perioperative infectious risk in urology: management of preoperative polymicrobial urine culture. A systematic review. By the infectious disease committee of the French Association of Urology
. Prog Urol
. 2019
;29
(5
):253
–62
.7.
Seymour
WC
, Liu
VX
, Iwashyna
TJ
, Brunkhorst
FM
, Rea
TD
, Scherag
A
, Assessment of clinical criteria for sepsis: for the third international consensus definitions for sepsis and septic shock (sepsis-3)
. JAMA
. 2016
;315
(8
):762
.8.
Caron
F
, Galperine
T
, Flateau
C
, Azria
R
, Bonacorsi
S
, Bruyère
F
, Practice guidelines for the management of adult community-acquired urinary tract infections
. Med Mal Infect
. 2018
;48
(5
):327
–58
.9.
Patel
SS
, Balfour
JA
, Bryson
HM
. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic proper-ties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections
. Drugs
. 1997
;53
(4
):637
–56
.10.
Scaglione
F
, Cicchetti
F
, Demartini
G
, Arcidiacono
M
. Fosfomycin distribution in the lower urinary tract after administration of fosfomycin trometamol salt
. Int J Clin Pharmacol Res
. 1994
;14
(3
):107
–9
.11.
Segre
G
, Bianchi
E
, Cataldi
A
, Zannini
G
. Pharmacokinetic profile of fosfomycin trometamol (Monuril)
. Eur Urol
. 1987
;13
(Suppl 1
):56
–63
. .12.
Illiano
E
, Trama
F
, Crocetto
F
, Califano
G
, Aveta
A
, Motta
G
, Prolapse surgery: what kind of antibiotic prophylaxis is necessary?
Urol Int
. 2021
;105
(9–10
):771
–6
.13.
Baboudjian
M
, Gondran-Tellier
B
, Abdallah
R
, Sichez
PC
, Akiki
A
, Gaillet
S
, Predictive risk factors of urinary tract infection following flexible ureteroscopy despite preoperative precautions to avoid infectious complications
. World J Urol
. 2020
;38
(5
):1253
–9
.14.
Peyronnet
B
, Pradere
B
, Brichart
N
, Bodin
T
, Bertrand
P
, Bruyère
F
, Complications associated with photoselective vaporization of the prostate: categorization by a panel of greenlight users according to clavien score and report of a single-center experience
. Urology
. 2014
;84
(3
):657
–64
.15.
Kehinde
EO
, Rotimi
VO
, Al-Awadi
K
, Abdul-Halim
H
, Boland
F
, Al-Hunayan
A
, Factors predisposing to urinary tract infection after J ureteral stent insertion
. J Urol
. 2002
;167
:1334
–7
.16.
Bonkat
G
, Rieken
M
, Rentsch
CA
, Wyler
S
, Feike
A
, Schäfer
J
, Improved detection of microbial ureteral stent colonisation by sonication
. World J Urol
. 2011
;29
:133
–8
.17.
Riedl
CR
, Plas
E
, Hübner
WA
, Zimmerl
H
, Ulrich
W
, Pflüger
H
. Bacterial colonization of ureteral stents
. Eur Urol
. 1999
;36
:53
–9
. .18.
Bruyere
F
, Traxer
O
, Saussine
C
, Lechevallier
E
. Infection et lithiase urinaire
. Progrès en Urologie
. 2008
;18
(12
):1015
–20
. .19.
Grabe
M
, Botto
H
, Cek
M
, Tenke
P
, Wagenlehner
FME
, Naber
KG
, Preoperative assessment of the patient and risk fac-tors for infectious complications and tentative classification of surgical field contamination of urological procedures
. World J Urol
. 2012
;30
(1
):39
–50
.20.
Tumbarello
M
, Trecarichi
EM
, Bassetti
M
, De Rosa
FG
, Spanu
T
, Di Meco
E
, Identifying patients harboring extended-spectrum-β-lactamase-producing enterobacteriaceae on hospital admission: derivation and validation of a scoring system
. Antimicrob Agents Chemother
. 2011
;55
(7
):3485
–90
.21.
Allali
S
, Bagueri
M
, Dimitri
M
, Lakmichi
M
, Dahami
Z
, Sarf
I
. Entérobactéries productrices de BLSE: prévalence, co-résistance et facteurs de risque; où sommes-nous
. Prog Urol
. 2015
;25
(13
):8
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
